Enzyme Inhibition in Drug Discovery and Development
The Good and the Bad
Albert P Li editor Chuang Lu editor
Format:Hardback
Publisher:John Wiley & Sons Inc
Published:26th Jan '10
Currently unavailable, and unfortunately no date known when it will be back
The science and applied approaches of enzyme inhibition in drug discovery and development
Offering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, Enzyme Inhibition in Drug Discovery and Development examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development.
With chapters written by over fifty leading experts in their fields, Enzyme Inhibition in Drug Discovery and Development fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the "good" inhibitions—desirable pharmacological effects—and "bad" inhibitions—drug–drug interactions and toxicity. The book discusses:
The drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment
The manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug–drug interactions
The inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathway
Through this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK.
"The description of each topic is clear, well organized and informative, making the book a useful or even essential high-level handbook." (ChemMedChem, November 2010)
ISBN: 9780470281741
Dimensions: 243mm x 163mm x 45mm
Weight: 1311g
880 pages